Efectos adversos de la vacunación por COVID-19 en jóvenes y adultos
Introducción: Ante la inesperada irrupción del virus SARS-CoV-2, causante del Covid-19, que desencadenó una nueva pandemia en pleno siglo XXI, ninguna nación estaba preparada para afrontar una situación de tal magnitud. Como resultado, se desató una competencia contrarreloj para desarrollar una vacu...
- Autores:
-
Pedraza Pedraza, Erika Liseth
Briceño Rondón, Luis Eduardo
Amaya Gualdrón, Maria Jimena
Diaz Chaparro, Mayerly
- Tipo de recurso:
- Trabajo de grado de pregrado
- Fecha de publicación:
- 2024
- Institución:
- Universidad Cooperativa de Colombia
- Repositorio:
- Repositorio UCC
- Idioma:
- spa
- OAI Identifier:
- oai:repository.ucc.edu.co:20.500.12494/56294
- Acceso en línea:
- https://hdl.handle.net/20.500.12494/56294
- Palabra clave:
- Covid-19
Efectos adversos
Vacunación
Covid-19
Literature review
Adverse effects
Vaccination
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by-nc-nd/4.0/
| id |
COOPER2_b42d2afc15becb6f20e7b35d4dcec814 |
|---|---|
| oai_identifier_str |
oai:repository.ucc.edu.co:20.500.12494/56294 |
| network_acronym_str |
COOPER2 |
| network_name_str |
Repositorio UCC |
| repository_id_str |
|
| dc.title.none.fl_str_mv |
Efectos adversos de la vacunación por COVID-19 en jóvenes y adultos |
| title |
Efectos adversos de la vacunación por COVID-19 en jóvenes y adultos |
| spellingShingle |
Efectos adversos de la vacunación por COVID-19 en jóvenes y adultos Covid-19 Efectos adversos Vacunación Covid-19 Literature review Adverse effects Vaccination |
| title_short |
Efectos adversos de la vacunación por COVID-19 en jóvenes y adultos |
| title_full |
Efectos adversos de la vacunación por COVID-19 en jóvenes y adultos |
| title_fullStr |
Efectos adversos de la vacunación por COVID-19 en jóvenes y adultos |
| title_full_unstemmed |
Efectos adversos de la vacunación por COVID-19 en jóvenes y adultos |
| title_sort |
Efectos adversos de la vacunación por COVID-19 en jóvenes y adultos |
| dc.creator.fl_str_mv |
Pedraza Pedraza, Erika Liseth Briceño Rondón, Luis Eduardo Amaya Gualdrón, Maria Jimena Diaz Chaparro, Mayerly |
| dc.contributor.advisor.none.fl_str_mv |
Contreras Ramos, Luz Mery |
| dc.contributor.author.none.fl_str_mv |
Pedraza Pedraza, Erika Liseth Briceño Rondón, Luis Eduardo Amaya Gualdrón, Maria Jimena Diaz Chaparro, Mayerly |
| dc.subject.proposal.spa.fl_str_mv |
Covid-19 Efectos adversos Vacunación |
| topic |
Covid-19 Efectos adversos Vacunación Covid-19 Literature review Adverse effects Vaccination |
| dc.subject.proposal.eng.fl_str_mv |
Covid-19 Literature review Adverse effects Vaccination |
| description |
Introducción: Ante la inesperada irrupción del virus SARS-CoV-2, causante del Covid-19, que desencadenó una nueva pandemia en pleno siglo XXI, ninguna nación estaba preparada para afrontar una situación de tal magnitud. Como resultado, se desató una competencia contrarreloj para desarrollar una vacuna que pudiera proteger a la población mundial y así mitigar la elevada mortalidad y los síntomas severos asociados con este virus. En el proceso de búsqueda de un biológico que pudiera erradicar esta enfermedad se implementaron diversos métodos de barrera para disminuir el riesgo de contagio contra el Covid-19, donde se pudo evidenciar el uso de diversos métodos para prevenir y mitigar su propagación: el disminuir el contacto físico, evitar saludar de mano, el distanciamiento de 1m entre persona y persona pero dichos métodos no eran tan eficaces para disminuir la mortalidad que se presentaba a nivel mundial Objetivo: Determinar los efectos adversos de la vacunación por Covid-19 en jóvenes y adultos. Metodología: Se realizó una investigación tipo revisión de la literatura que estuvo conformada por artículos y revistas científicas, relacionados con los efectos adversos de la vacunación contra Covid-19, se inició por una búsqueda en diferentes bases de datos científicas donde se realizó una selección de los artículos por medio de criterios de inclusión, se tuvo en cuenta aquellos artículos que cumplían con las indicaciones dadas por los investigadores, como la edad, que se haya administrado cualquier biológico contra el Covid-19, y presentación de efectos secundarios post- vacunación, posterior a esta selección de artículos se realizó revisión y recolección da datos de cada uno de ellos para determinar los efectos que producían las diferentes vacunas administradas. Resultados: En la revisión de la literatura se encontró que con los diferentes tipos de vacunas se presentaban diferentes efectos adversos en los cuales se observaban los siguientes resultados, Pfizer BioNTech (Comirnaty Tozinameran BNT162b2)con la primera, segunda y tercera dosis con un 10,9 % – 50,1% el efecto secundario más prevalente fue la cefalea, en la vacunación con Moderna (ARNm1273) con la primera, segunda y tercera dosis con un 11,5 % – 66,7% el efecto secundario más prevalente es fue la cefalea, AstraZeneca(Vaxzevria AZD1222 Covishield) con la primera, segunda y tercera dosis de este biológico se observó que con un 49, 6 % el efecto adverso más prevalente fue el dolor muscular, en la vacunación con Jonhson & Jonhson o Janssen (Ad26.COV2.S) se observó que el efecto más prevalente con un 34,4 % era el malestar general, con la vacuna Sinovac(CoronaVac) el efecto más prevalente con un 3,5 – 32,23 % fue el dolor en el sitio de punción y con el biológico Novavax(NVXCoV2373), se observó que el efecto mas prevalente con un 80% fue el dolor en el sitio de punción .Conclusiones: Los efectos más prevalentes tras la vacunación contra el Covid- 19 encontrados en la revisión literaria de los artículos fueron cefalea, fiebre y dolor en el sitio de punción independientemente del tipo de vacuna y dosis administrada. |
| publishDate |
2024 |
| dc.date.accessioned.none.fl_str_mv |
2024-07-11T15:55:21Z |
| dc.date.available.none.fl_str_mv |
2024-07-11T15:55:21Z |
| dc.date.issued.none.fl_str_mv |
2024-07-11 |
| dc.type.none.fl_str_mv |
Trabajo de grado - Pregrado |
| dc.type.coar.none.fl_str_mv |
http://purl.org/coar/resource_type/c_7a1f |
| dc.type.content.none.fl_str_mv |
Text |
| dc.type.driver.none.fl_str_mv |
info:eu-repo/semantics/bachelorThesis |
| dc.type.redcol.none.fl_str_mv |
http://purl.org/redcol/resource_type/TP |
| dc.type.version.none.fl_str_mv |
info:eu-repo/semantics/acceptedVersion |
| format |
http://purl.org/coar/resource_type/c_7a1f |
| status_str |
acceptedVersion |
| dc.identifier.citation.none.fl_str_mv |
Amaya Gualdrón, M. J., Pedraza Pedraza, E. L., Briceño Rondón, L. E. y Diaz Chaparro, M. (2024). Efectos Adversos de la Vacunación por Covid – 19 en Jóvenes y Adultos. [Tesis de pregrado, Universidad Cooperativa de Colombia]. Repositorio Institucional Universidad Cooperativa de Colombia. https://hdl.handle.net/20.500.12494/56294 |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/20.500.12494/56294 |
| identifier_str_mv |
Amaya Gualdrón, M. J., Pedraza Pedraza, E. L., Briceño Rondón, L. E. y Diaz Chaparro, M. (2024). Efectos Adversos de la Vacunación por Covid – 19 en Jóvenes y Adultos. [Tesis de pregrado, Universidad Cooperativa de Colombia]. Repositorio Institucional Universidad Cooperativa de Colombia. https://hdl.handle.net/20.500.12494/56294 |
| url |
https://hdl.handle.net/20.500.12494/56294 |
| dc.language.iso.none.fl_str_mv |
spa |
| language |
spa |
| dc.relation.references.none.fl_str_mv |
Abad-Corpa, E., Sánchez-López, D., & Moreno-Casbas, M. T. (2021). Scoping review sobre las recomendaciones para el aislamiento domiciliario en la pandemia de COVID-19. Enfermería Clínica, 31, 94–99. https://doi.org/10.1016/J.ENFCLI.2020.05.007 Aboud, F. M., Hussein, R. S., & Hassan, R. M. (2023). Safety and reported adverse effects of coronavirus disease-2019 (COVID-19) vaccines in patients with rheumatic diseases. Egyptian Rheumatologist, 45(2), 133–137. https://doi.org/10.1016/j.ejr.2022.12.003 Abukhalil, A. D., Shatat, S. S., Abushehadeh, R. R., Al-Shami, N., Naseef, H. A., & Rabba, A. (2023). Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community. BMC Infectious Diseases, 23(5), 1–15. https://doi.org/10.1186/s12879-022-07974-3 Aguilar Ramírez, P., Yanina Enriquez Valencia, ;, Carlos, ;, Carrillo, Q., Valencia Ayala, ; Edward, De, J., Delgado, L., & Pareja Cruz, A. (2020). Pruebas diagnósticas para la COVID-19: la importancia del antes y el después. Horizonte Médico (Lima), 20(2), e1231–e1231. https://doi.org/10.24265/HORIZMED.2020.V20N2.14 Al Salmi, A., Al Khamisani, M., Al Shibli, A., & Al Maqbali, S. (2022). Adverse cutaneous reactions reported post COVID-19 vaccination in Al Buraimi governorate, Sultanate of Oman. Dermatologic Therapy, 35(11), 1–7. https://doi.org/10.1111/dth.15820 Aldali, H. J., Aldali, J. A., Alotaibi, B. A., Alasiri, G. A., Alromih, A. M., Elsokkary, E. M., Aldali, A. Z., & Almeziny, A. (2023). Evaluating the Adverse Events Associated with Three Doses of the COVID-19 Vaccination in Adults in the Western Region of Saudi Arabia: A Cross-Sectional Study. Vaccines, 11(2), 266–276. https://doi.org/10.3390/vaccines11020266 Alghamdi, A. N., Alotaibi, M. I., Alqahtani, A. S., Al Aboud, D., & Abdel-Moneim, A. S. (2021). BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees. Frontiers in Medicine, 8(1), 1–10. https://doi.org/10.3389/fmed.2021.760047 Alkhalifah, J. M., Al Seraihi, A., Al-Tawfiq, J. A., Alshehri, B. F., Alhaluli, A. H., Alsulais, N. M., Alessa, M. M., Seddiq, W., Aljeri, T., Qahtani, M. H., Barry, M., & Al-Otaiby, M. (2023). Pattern of self-reported adverse events related to COVID-19 vaccines in Saudi Arabia: A nationwide study. Frontiers in Public Health, 11(1), 1–10. https://doi.org/10.3389/fpubh.2023.1043696 Almalki, O. S., Santali, E. Y., Alhothali, A. A., Ewis, A. A., Shady, A., Fathelrahman, A. I., & Abdelwahab, S. F. (2023). The role of blood groups, vaccine type and gender in predicting the severity of side effects among university students receiving COVID-19 vaccines. BMC Infectious Diseases, 23(1), 1–11. https://doi.org/10.1186/s12879-023-08363-0 Alzarea, A. I., Khan, Y. H., Alatawi, A. D., Alanazi, A. S., Alzarea, S. I., Butt, M. H., Almalki, Z. S., Alahmari, A. K., & Mallhi, T. H. (2022). Surveillance of Post-Vaccination Side Effects of COVID-19 Vaccines among Saudi Population: A Real-World Estimation of Safety Profile. Vaccines, 10(6), 924–940. https://doi.org/10.3390/vaccines10060924 Andrzejczak Grzadko, S., Czudy, Z., & Donderska, M. (2021). Side effects after COVID-19 vaccinations among residents of Poland. Eur Rev Med Pharmacol Sci , 25(11), 4418–4421. https://doi.org/10.26355/eurrev_202106_26153 Babaee, E., Amirkafi, A., Tehrani-Banihashemi, A., SoleimanvandiAzar, N., Eshrati, B., Rampisheh, Z., Asadi-Aliabadi, M., & Nojomi, M. (2022). Adverse effects following COVID-19 vaccination in Iran. BMC Infectious Diseases, 22(1), 247–255. https://doi.org/10.1186/s12879-022-07411-5 Bakasis, A. D., Mavragani, C. P., Voulgari, P. V., Gerolymatou, N., Argyropoulou, O. D., Vlachoyiannopoulos, P. G., Skopouli, F. N., Tzioufas, A. G., & Moutsopoulos, H. M. (2022). COVID-19: Clinical features and outcomes in unvaccinated 2-dose and 3-dose vaccinated against SARS-CoV-2 patients with systemic autoimmune and autoinflammatory rheumatic diseases. Journal of Autoimmunity, 131(1), 1–6. https://doi.org/10.1016/j.jaut.2022.102846 Chong-Valbuena, A., De-Jesús-María, I., Agurto-Ramírez, A., Puchades-Gimeno, F., & Melero-García, M. (2022). Safety of Pfizer-BioNTech vaccine in a cohort of healthcare providers: Differences between naïve and previously infected by SARS-CoV-2. Vaccine, 40(28), 3818–3820. https://doi.org/10.1016/j.vaccine.2022.05.015 Corominas, J., Garriga, C., Prenafeta, A., Moros, A., Cañete, M., Barreiro, A., González-González, L., Madrenas, L., Güell, I., Clotet, B., Izquierdo-Useros, N., Raïch-Regué, D., Gallemí, M., Blanco, J., Pradenas, E., Trinité, B., Prado, J. G., Blanch-Lombarte, O., Pérez-Caballero, R., … Ferrer, L. (2023). Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial. The Lancet Regional Health - Europe, 28(1), 1–17. https://doi.org/10.1016/j.lanepe.2023.100613 Corum J., & Zimmer C. (2021). Cómo funciona la vacuna contra la COVID-19 de Pfizer-BioNTech. The New York Time. https://www.nytimes.com/es/interactive/2021/health/pfizer-biontech-vacuna-covid.html Dhamanti, I., Suwantika, A. A., Adlia, A., Yamani, L. N., & Yakub, F. (2023). Adverse Reactions of COVID-19 Vaccines: A Scoping Review of Observational Studies. International Journal of General Medicine, 16(1), 609–618. https://doi.org/10.2147/IJGM.S400458 Díaz Castrillón, F., & Toro Montoya, A. I. (2020). Artículo de revisión SARS-CoV-2/COVID-19: el virus, la enfermedad y la pandemia SARS-CoV-2/COVID-19: The virus, the disease and the pandemic. Medicina & Laboratorio, 24(3), 183–205. https://dialnet.unirioja.es/servlet/articulo?codigo=8741673 Ebinger, J. E., Lan, R., Sun, N., Wu, M., Joung, S., Botwin, G. J., Botting, P., Al-Amili, D., Aronow, H., Beekley, J., Coleman, B., Contreras, S., Cozen, W., Davis, J., Debbas, P., Diaz, J., Driver, M., Fert-Bober, J., Gu, Q., … Minissian, M. B. (2021). Symptomology following mRNA vaccination against SARS-CoV-2. Preventive Medicine, 153(1), 1–8. https://doi.org/10.1016/j.ypmed.2021.106860 Enayatrad, M., Mahdavi, S., Aliyari, R., Sahab-Negah, S., Nili, S., Fereidouni, M., Mangolian Shahrbabaki, P., Ansari-Moghaddam, A., Heidarzadeh, A., Shahraki-Sanavi, F., Fateh, M., Khajeha, H., Emamian, Z., Behmanesh, E., Sheibani, H., Abbaszadeh, M., Jafari, R., Valikhani, M., Binesh, E., … Emamian, M. H. (2023a). Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system. BMC Infectious Diseases, 23(1), 150. https://doi.org/10.1186/s12879-023-08103-4 Enayatrad, M., Mahdavi, S., Aliyari, R., Sahab-Negah, S., Nili, S., Fereidouni, M., Mangolian Shahrbabaki, P., Ansari-Moghaddam, A., Heidarzadeh, A., Shahraki-Sanavi, F., Fateh, M., Khajeha, H., Emamian, Z., Behmanesh, E., Sheibani, H., Abbaszadeh, M., Jafari, R., Valikhani, M., Binesh, E., … Emamian, M. H. (2023b). Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system. BMC Infectious Diseases, 23(1), 150–165. https://doi.org/10.1186/s12879-023-08103-4 Ferrara, P., Ponticelli, D., Losa, L., Romeo, C., Magliuolo, R., Vitale, A., Zampella, A., Alleanza, L., Borrelli, M., Schiavone, B., & Mantovani, L. G. (2023). Risk of Repeated Adverse Effects following Booster Dose of mRNA COVID-19 Vaccine: Results from the MOSAICO Study. Vaccines, 11(2), 247–261. https://doi.org/10.3390/vaccines11020247 Fraiman, J., Erviti, J., Jones, M., Greenland, S., Whelan, P., Kaplan, R. M., & Doshi, P. (2022). Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine, 40(40), 5798–5805. https://doi.org/10.1016/j.vaccine.2022.08.036 Galanis, P., Katsiroumpa, A., Vraka, I., Chrysagi, V., Siskou, O., Konstantakopoulou, O., Katsoulas, T., Gallos, P., & Kaitelidou, D. (2023). Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from Greece. Vacunas, 24(3), 210–217. https://doi.org/10.1016/j.vacun.2023.05.005 Gedik, M. S., Kilci, A. İ., Hakkoymaz, H., Küçük, Ö. F., Solak, Y., Basan, N. M., & Çıkrıkçı, Y. E. (2023). Evaluation of patients of vaccine side effects after the COVID-19 vaccine. Revista Da Associacao Medica Brasileira, 69(1), 147–152. https://doi.org/10.1590/1806-9282.20221035 Giuliano, A., Kuter, B., Pilon‐Thomas, S., Whiting, J., Mo, Q., Leav, B., Sirak, B., Cubitt, C., Dukes, C., Isaacs‐Soriano, K., Kennedy, K., Ball, S., Dong, N., Jain, A., Hwu, P., & Lancet, J. (2023). Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients. Cancer Communications, 43(7), 749–764. https://doi.org/10.1002/cac2.12453 Hammershaimb, E. A., Campbell, J. D., & O’Leary, S. T. (2023). Coronavirus Disease-2019 Vaccine Hesitancy. Pediatric Clinics of North America, 70(2), 243–257. https://doi.org/10.1016/j.pcl.2022.12.001 INSPMX. (2020). ¿Qué son los coronavirus? Instituto Nacional Salud Mexico. https://insp.mx/nuevo-coronavirus-2019/que-es-nuevo-coronavirus.html Izak, M., Stoyanov, E., Dezuraev, K., & Shinar, E. (2022). Correlation of Anti-SARS-CoV-2 S1-specific IgG antibody levels and adverse events following vaccination with BNT162b2 mRNA COVID-19 vaccine in healthcare workers. Vaccine, 40(3), 428–431. https://doi.org/10.1016/j.vaccine.2021.11.082 Jahan, N., Rahman, F. I., Saha, P., Ether, S. A., Roknuzzaman, A. S. M., Sarker, R., Kalam, K. T., Haq, K., Nyeen, J., Himi, H. Z., Nazmul Hossain, M., Chowdhury, M. H., Uddin, M. M., & Alam, N. H. (2021). Side effects following administration of the first dose of Oxford-AstraZeneca’s covishield vaccine in Bangladesh: A cross-sectional study. Infectious Disease Reports, 13(4), 888–901. https://doi.org/10.3390/IDR13040080 Jorda, A., Bergmann, F., Ristl, R., Radner, H., Sieghart, D., Aletaha, D., & Zeitlinger, M. (2023). Association between reactogenicity and immunogenicity after BNT162b2 booster vaccination: a secondary analysis of a prospective cohort study. Clinical Microbiology and Infection, 29(9), 1188–1195. https://doi.org/10.1016/j.cmi.2023.05.028 Kanokudom, S., Assawakosri, S., Suntronwong, N., Chansaenroj, J., Auphimai, C., Nilyanimit, P., Vichaiwattana, P., Thongmee, T., Yorsaeng, R., Duangchinda, T., Chantima, W., Pakchotanon, P., Srimuan, D., Thatsanatorn, T., Klinfueng, S., Mongkolsapaya, J., Sudhinaraset, N., Wanlapakorn, N., Honsawek, S., & Poovorawan, Y. (2022). Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine. Vaccine, 40(39), 5657–5663. https://doi.org/10.1016/j.vaccine.2022.08.033 Karaali, R., Öykü Dinç, H. Ö., İnanç Balkan, İ., Can, G., Keskin, E., Çolak, H., Daşdemir, F. O., Aydoğan, O., Budak, B., Kaya, S. Y., Kocazeybek, B., & Saltoğlu, N. (2023). Homologous or heterologous COVID-19 vaccine schemes: comparison of immune responses and side effects. Diagnostic Microbiology and Infectious Disease, 107(2), 1–6. https://doi.org/10.1016/j.diagmicrobio.2023.116017 Kaur, S., Singh, A., Saini, S., Rohilla, L., Kaur, J., Chandi, A., Kaur, G., Singh, M., Kumar, P., Soni, S., Kajal, K., Naik, N., Malhotra, P., Verma, S., Gupta, M., Devnani, M., Das, K., Pandav, S., & Puri, G. D. (2022). Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey. Indian Journal of Medical Research, 155(1), 123–129. https://doi.org/10.4103/ijmr.ijmr_1221_21 Kermer, P., Abdalla, Y., Klein, G., & Lüers, C. (2023). Acute adverse events of Sars-CoV2 vaccines: Experiences from a health care worker vaccination campaign in two municipal hospitals in northwest Germany. Vaccine: X, 13(1), 1–6. https://doi.org/10.1016/j.jvacx.2022.100257 Lee, K. M. N., Junkins, E. J., Luo, C., Fatima, U. A., Cox, M. L., & Clancy, K. B. H. (2022). Investigating trends in those who experience menstrual bleeding changes after SARS-CoV-2 vaccination. Science Advances, 8(28), 1–15. https://doi.org/10.1126/sciadv.abm7201 Li, D., Debbas, P., Mujukian, A., Cheng, S., Braun, J., McGovern, D. P. B., Melmed, G. Y., Banty, A., Feldman, E., Ha, C., Lee, S., Rabizadeh, S., Stein, T., Solomon, T., Syal, G., Targan, S., Vasiliauskas, E., Ziring, D., Bonthala, N., … Damas, O. (2023). Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD. Inflammatory Bowel Diseases, 29(6), 883–887. https://doi.org/10.1093/ibd/izac174 Majumder, M. A. A., Singh, K., Johnson, W., Rajasundaram, A., Gupta, S., Gaur, U., Kumar, S., Chatterjee, M., Fazle Rabbi, A. M., Sangishetti, V. P., Rahman, S., Campbell, M. H., Harewood, H., Bharatha, A., Krishnamurthy, K., Kabir, R., Parsa, A. D., Mohammmad, S., Haque, M., & Razzaque, M. S. (2023). Evaluation of Short-Term Side Effects Following the First Dose of COVID-19 Vaccines Among Physicians and Dentists: A Cross-Sectional Study from India. Journal of Multidisciplinary Healthcare, 16(2), 161–174. https://doi.org/10.2147/JMDH.S390364 Mallah, S. I., Alawadhi, A., Jawad, J., Wasif, P., Alsaffar, B., Alalawi, E., Mohamed, A. M., Butler, A. E., Alalawi, B., Qayed, D., Almahari, S. A., Mubarak, A., Mubarak, A., Saeed, S., Humaidan, A., Kumar, N., Atkin, S., & Alqahtani, M. (2023). Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals. Vaccine, 41(12), 1925–1933. https://doi.org/10.1016/j.vaccine.2023.01.032 Marfoh, K., Samba, A., Okyere, E., Acheampong, F., Owusu, E., Darko, D. N. A., Zakariah, J., Mensa, H., Aidoo, E., & Mohammed, Y. (2023). Adverse events following immunisation (AEFI) of COVISHIELD vaccination among healthcare workers in Ghana. BMJ Open, 13(6), e061643. https://doi.org/10.1136/bmjopen-2022-061643 Mascellino, M. T., Di Timoteo, F., De Angelis, M., & Oliva, A. (2021). Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. Infection and Drug Resistance, 14(1), 3459–3476. https://doi.org/10.2147/IDR.S315727 McMahon, D. E., Amerson, E., Rosenbach, M., Lipoff, J. B., Moustafa, D., Tyagi, A., Desai, S. R., French, L. E., Lim, H. W., Thiers, B. H., Hruza, G. J., Blumenthal, K. G., Fox, L. P., & Freeman, E. E. (2021). Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. Journal of the American Academy of Dermatology, 85(1), 46–55. https://doi.org/10.1016/j.jaad.2021.03.092 Melián-Rivas, A., Calcumil-Herrera, P., Boin-Bakit, C., Carrasco-Soto, R., Melián-Rivas, A., Calcumil-Herrera, P., Boin-Bakit, C., & Carrasco-Soto, R. (2020). Detection of COVID-19 (SARS-CoV-2) by Saliva: A Low-invasive Diagnostic Alternative. International Journal of Odontostomatology, 14(3), 316–320. https://doi.org/10.4067/S0718-381X2020000300316 Menni, C., Klaser, K., May, A., Polidori, L., Capdevila, J., Louca, P., Sudre, C. H., Nguyen, L. H., Drew, D. A., Merino, J., Hu, C., Selvachandran, S., Antonelli, M., Murray, B., Canas, L. S., Molteni, E., Graham, M. S., Modat, M., Joshi, A. D., … Spector, T. D. (2021). Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet Infectious Diseases, 21(7), 939–949. https://doi.org/10.1016/S1473-3099(21)00224-3 Nassar, R. I., Barakat, M., Thiab, S., El-Hajji, F., Barqawi, H., El-Huneidi, W., Basheti, I. A., & Abu-Gharbieh, E. (2022). Web-Based Reporting of Post-Vaccination Symptoms for Inactivated COVID-19 Vaccines in Jordan: A Cross-Sectional Study. Vaccines, 11(1), 44–57. https://doi.org/10.3390/vaccines11010044 Word Health Organization. (2023). Enfermedad por coronavirus (COVID-19): vacunas y seguridad de las vacunas. WHO. https://www.who.int/es/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines Organización Panamericana de la Salud. (2021). La COVID-19 y Adultos Mayores -. PAHO. https://www.paho.org/es/envejecimiento-saludable/covid-19-adultos-mayores Pignatti, P., Ramirez, G. A., Russo, M., Marraccini, P., Nannipieri, S., Asperti, C., Torre, F. Della, Tiri, A., Gatti, B. M., Gurrado, A., Meriggi, A., Benanti, G., Cilona, M. B., Pigatto, P., Burastero, S. E., Dagna, L., & Yacoub, M.-R. (2023). Hypersensitivity reactions to anti-SARS-CoV-2 vaccines: Basophil reactivity to excipients. Vaccine, 41(32), 4693–4699. https://doi.org/10.1016/j.vaccine.2023.06.039 Rayamajhi, S., Rafi, Md. A., Tripathi, N., Dongol, A. S., Pandey, M., Rayamajhi, S., Bhandari, S., Shrestha, P., Hasan, M. T., & Hossain, Md. G. (2022). Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal. PLOS ONE, 17(8), 1–10. https://doi.org/10.1371/journal.pone.0272729 Roche Farma, S. A. (2022). Patología. Roche Plus. https://www.rocheplus.es/areas-terapeuticas/covid-19/patologia.html Romero Saritama, J., Simaluiza, J., & Fernandez, H. (2021). Medidas de prevención para evitar el contagio por la COVID-19: de lo cotidiano a lo técnico-científico. Revista Española de Salud Publica, 95(1), 1–14. https://www.scielosp.org/article/resp/2021.v95/e202104051/es/ Rosen, J. E., Chang, S. S. E., Williams, S., Lee, J. S., Han, D. H., Agrawal, N., Joo, J. H., Hsieh, G., Reinecke, K., & Liao, J. M. (2023). Association between Risk Communication Format and Perceived Risk of Adverse Events after COVID-19 Vaccination among US Adults. Healthcare (Switzerland), 11(3), 380–391. https://doi.org/10.3390/healthcare11030380 Safarnezhad Tameshkel, F., Abedin Dargoush, S., Goudarzi, M., Tabibzadeh, A., Ghiaseddin, A., Ranjbar, M., Alimohamadi, Y., Zamani, F., Vaez, A., Rahimian, N., Jamshidi Makiani, M., Divsalar, F., Gholizadeh, E., & Karbalaie Niya, M. H. (2023). A Retrospective Study on the Gam-COVID-Vac (Sputnik V) COVID-19 Vaccine Short-Term Efficacy and Side Effects in Iranian Healthcare Providers. Archives of Clinical Infectious Diseases, 18(3), 1–6. https://doi.org/10.5812/archcid-133173 Sen, P., Ravichandran, N., Nune, A., Lilleker, J. B., Agarwal, V., Kardes, S., Kim, M., Day, J., Milchert, M., Gheita, T., Salim, B., Velikova, T., Gracia-Ramos, A. E., Parodis, I., O’Callaghan, A. S., Nikiphorou, E., Chatterjee, T., Tan, A. L., Cavagna, L., … Zimba, O. (2023). COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study. Rheumatology (United Kingdom), 62(1), 65–76. https://doi.org/10.1093/rheumatology/keac305 Sheng, W. H., Ieong, S. M., Lin, P. H., Hsieh, M. J., Yang, H. C., Pan, C. F., Chao, T. L., Chang, S. Y., & Chang, S. C. (2023). Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine. Journal of the Formosan Medical Association, 122(2), 121–131. https://doi.org/10.1016/j.jfma.2022.09.004 Siti, F., Iwan, S. D., Muflih, M., Thomas Aquino Erjinyuare, A., Rachmat, S., & Ahmat, P. (2022). Factors Associated with Adverse Events Following the First Dose of COVID-19 Immunization in Indonesia. Korean Journal of Adult Nursing, 34(3), 249–257. https://doi.org/10.7475/kjan.2022.34.3.249 Tanaka, H., Mukai, J., Kushibiki, K., Mizushima, S., Maeda, K., Fujimoto, Y., Sawada, R., Oda, M., Okuda, H., Yamaki, M., Hashiguchi, S., Kawai, I., Kawaguchi, I., Masuda, N., & Matsushita, H. (2023). Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers. Vaccine, 41(2), 365–371. https://doi.org/10.1016/j.vaccine.2022.11.049 Taşlidere, B., Sönmez, E., & Özdemır, S. (2023). Evaluation of patients admitted to the emergency department after Coronavac (Sinovac) vaccination? Journal of Experimental and Clinical Medicine (Turkey), 40(1), 80–84. https://doi.org/10.52142/omujecm.40.1.17 Torres, E. S., Nava Leyva, H., Teresa, A., García, R., Sánchez González, F. J., Huerta, G., & || G. (2020). Equipo de protección personal y COVID-19. Cirujano General, 42(2), 116–123. https://doi.org/10.35366/95370 Word Health Organization. (n.d.). COVID-19: cronología de la actuación de la OMS. Organización Mundial de La Salud. Retrieved September 11, 2023, from https://www.who.int/es/news/item/27-04-2020-who-timeline---covid-19 Word Health Organization. (2020). Coronavirus. WHO. https://www.who.int/es/health-topics/coronavirus#tab=tab_1 Word Health Organization. (2021). Preguntas y respuestas sobre la transmisión de la COVID-19. Www.Who.Int. https://www.who.int/es/news-room/questions-and-answers/item/coronavirus-disease-covid-19-how-is-it-transmitted Xiao, N., Xu, X., Ma, Z., Yu, X., Feng, Y., Li, B., Liu, Y., He, G., Fan, J., Li, B., & Zhao, X. (2023). Sleep quality was associated with adverse reactions after coronavirus disease 2019 vaccination among healthcare workers: A longitudinal paired study. Frontiers in Behavioral Neuroscience, 16(1), 1–10. https://doi.org/10.3389/fnbeh.2022.867650 Zeitoun, A., Hallit, S., Chehade, S., Ibrahim, A., Helali, M., Allam, C., & Karam, R. (2023). A 1-year analysis of adverse events following COVID-19 vaccination in Lebanon: a retrospective study. Journal of Pharmaceutical Policy and Practice, 16(1), 24–36. https://doi.org/10.1186/s40545-023-00528-1 |
| dc.rights.uri.none.fl_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| dc.rights.accessrights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.creativecommons.none.fl_str_mv |
Attribution-NonCommercial-NoDerivatives 4.0 International |
| dc.rights.coar.none.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by-nc-nd/4.0/ Attribution-NonCommercial-NoDerivatives 4.0 International http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.extent.none.fl_str_mv |
77 p. |
| dc.format.mimetype.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Universidad Cooperativa de Colombia, Facultad de Ciencias de la Salud, Enfermería, Bucaramanga |
| dc.publisher.program.none.fl_str_mv |
Enfermería |
| dc.publisher.faculty.none.fl_str_mv |
Ciencias de la Salud |
| dc.publisher.place.none.fl_str_mv |
Bucaramanga |
| dc.publisher.branch.none.fl_str_mv |
Bucaramanga |
| publisher.none.fl_str_mv |
Universidad Cooperativa de Colombia, Facultad de Ciencias de la Salud, Enfermería, Bucaramanga |
| institution |
Universidad Cooperativa de Colombia |
| bitstream.url.fl_str_mv |
https://repository.ucc.edu.co/bitstreams/51cebfb5-ff87-469e-9c9c-1f37be41314f/download https://repository.ucc.edu.co/bitstreams/7778d59f-e819-47a7-a690-98379fe77b71/download https://repository.ucc.edu.co/bitstreams/4622c88d-a362-4070-9411-2b694c45d09c/download https://repository.ucc.edu.co/bitstreams/06442f88-82f8-46f4-a993-cd0733b831a3/download https://repository.ucc.edu.co/bitstreams/61ead119-71cd-4c80-9a17-7b20d1e2cd0c/download https://repository.ucc.edu.co/bitstreams/1aaca000-7d5e-43a3-9d97-c823533511cc/download https://repository.ucc.edu.co/bitstreams/85003123-cae1-4b49-90c0-ebcfb1149764/download https://repository.ucc.edu.co/bitstreams/51a89db6-e284-4ac7-94ad-d706a244155f/download https://repository.ucc.edu.co/bitstreams/b39a6e45-bc71-498e-b159-8666a3a63fa0/download https://repository.ucc.edu.co/bitstreams/4e66b7fc-c551-4f1e-b36c-211ed63950ab/download https://repository.ucc.edu.co/bitstreams/4ee33d13-ebcb-4e23-8b77-bbc057658061/download |
| bitstream.checksum.fl_str_mv |
4460e5956bc1d1639be9ae6146a50347 3bce4f7ab09dfc588f126e1e36e98a45 0a6425b3e32dd933039ed3fe876bf318 43e9c7e9b74b11d5ad6d9ea6cdb930c3 b06d0e01374e60127e2bb8dd6458750b 56bbb4247460312c49fdbecb2ef05710 776071ce79c3e8d0d21a21c5e41976b7 7c3dd69c76a0e5599bd3ff2f189ae271 17f574431e6e5aeb0eb9f58aded65ad0 98e13e821c95014cd604061e84e74f5f b712f1c96592862d07eddc9f185bd545 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 MD5 MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional Universidad Cooperativa de Colombia |
| repository.mail.fl_str_mv |
bdigital@metabiblioteca.com |
| _version_ |
1814246928315056128 |
| spelling |
Contreras Ramos, Luz MeryPedraza Pedraza, Erika LisethBriceño Rondón, Luis EduardoAmaya Gualdrón, Maria JimenaDiaz Chaparro, Mayerly2024-07-11T15:55:21Z2024-07-11T15:55:21Z2024-07-11Amaya Gualdrón, M. J., Pedraza Pedraza, E. L., Briceño Rondón, L. E. y Diaz Chaparro, M. (2024). Efectos Adversos de la Vacunación por Covid – 19 en Jóvenes y Adultos. [Tesis de pregrado, Universidad Cooperativa de Colombia]. Repositorio Institucional Universidad Cooperativa de Colombia. https://hdl.handle.net/20.500.12494/56294https://hdl.handle.net/20.500.12494/56294Introducción: Ante la inesperada irrupción del virus SARS-CoV-2, causante del Covid-19, que desencadenó una nueva pandemia en pleno siglo XXI, ninguna nación estaba preparada para afrontar una situación de tal magnitud. Como resultado, se desató una competencia contrarreloj para desarrollar una vacuna que pudiera proteger a la población mundial y así mitigar la elevada mortalidad y los síntomas severos asociados con este virus. En el proceso de búsqueda de un biológico que pudiera erradicar esta enfermedad se implementaron diversos métodos de barrera para disminuir el riesgo de contagio contra el Covid-19, donde se pudo evidenciar el uso de diversos métodos para prevenir y mitigar su propagación: el disminuir el contacto físico, evitar saludar de mano, el distanciamiento de 1m entre persona y persona pero dichos métodos no eran tan eficaces para disminuir la mortalidad que se presentaba a nivel mundial Objetivo: Determinar los efectos adversos de la vacunación por Covid-19 en jóvenes y adultos. Metodología: Se realizó una investigación tipo revisión de la literatura que estuvo conformada por artículos y revistas científicas, relacionados con los efectos adversos de la vacunación contra Covid-19, se inició por una búsqueda en diferentes bases de datos científicas donde se realizó una selección de los artículos por medio de criterios de inclusión, se tuvo en cuenta aquellos artículos que cumplían con las indicaciones dadas por los investigadores, como la edad, que se haya administrado cualquier biológico contra el Covid-19, y presentación de efectos secundarios post- vacunación, posterior a esta selección de artículos se realizó revisión y recolección da datos de cada uno de ellos para determinar los efectos que producían las diferentes vacunas administradas. Resultados: En la revisión de la literatura se encontró que con los diferentes tipos de vacunas se presentaban diferentes efectos adversos en los cuales se observaban los siguientes resultados, Pfizer BioNTech (Comirnaty Tozinameran BNT162b2)con la primera, segunda y tercera dosis con un 10,9 % – 50,1% el efecto secundario más prevalente fue la cefalea, en la vacunación con Moderna (ARNm1273) con la primera, segunda y tercera dosis con un 11,5 % – 66,7% el efecto secundario más prevalente es fue la cefalea, AstraZeneca(Vaxzevria AZD1222 Covishield) con la primera, segunda y tercera dosis de este biológico se observó que con un 49, 6 % el efecto adverso más prevalente fue el dolor muscular, en la vacunación con Jonhson & Jonhson o Janssen (Ad26.COV2.S) se observó que el efecto más prevalente con un 34,4 % era el malestar general, con la vacuna Sinovac(CoronaVac) el efecto más prevalente con un 3,5 – 32,23 % fue el dolor en el sitio de punción y con el biológico Novavax(NVXCoV2373), se observó que el efecto mas prevalente con un 80% fue el dolor en el sitio de punción .Conclusiones: Los efectos más prevalentes tras la vacunación contra el Covid- 19 encontrados en la revisión literaria de los artículos fueron cefalea, fiebre y dolor en el sitio de punción independientemente del tipo de vacuna y dosis administrada.With the unexpected outbreak of the SARS-CoV-2 virus, the cause of Covid-19, which triggered a new pandemic in the 21st century, no nation was prepared to face a situation of such magnitude. As a result, a race against time was unleashed to develop a vaccine that could protect the world's population and thus mitigate the high mortality and severe symptoms associated with this virus. In the process of searching for a biologic that could eradicate this disease, several barrier methods were implemented to reduce the risk of contagion against Covid-19, where the use of various methods to prevent and mitigate its spread was evidenced: reducing physical contact, avoiding shaking hands, the distance of 1m between people, but these methods were not as effective in reducing the mortality that occurred worldwide. Objective: To determine the adverse effects of Covid-19 vaccination in young people and adults. Methodology: A literature review type research was carried out, which consisted of articles and scientific journals, related to the adverse effects of vaccination against Covid-19, starting with a search in different scientific databases where a selection of articles was made by means of inclusion criteria, The articles that complied with the indications given by the researchers, such as age, having administered any biologic against Covid-19, and presentation of post-vaccination side effects, were taken into account. After this selection of articles, a review and data collection of each one of them was carried out to determine the effects produced by the different vaccines administered. Results: In the literature review, it was found that different types of vaccines presented different adverse effects in which the following results were observed: Pfizer BioNTech (Comirnaty Tozinameran BNT162b2) with the first, second and third doses with 10.9% – 50.1% the most prevalent side effect was headache, in vaccination with Moderna (mRNA1273) with the first, second and third doses with 11.5% – 66.7% the most prevalent side effect was headache , AstraZeneca (Vaxzevria AZD1222 Covishield) with the first, second and third doses of this biological it was observed that with 49.6% the most prevalent adverse effect was muscle pain, in vaccination with Jonhson & Jonhson or Janssen (Ad26.COV2 .S) it was observed that the most prevalent effect with 34.4% was general discomfort, with the Sinovac vaccine (CoronaVac) the most prevalent effect with 3.5 - 32.23% was pain at the puncture site and with the biological Novavax (NVXCoV2373), it was observed that the most prevalent effect with 80% was pain at the puncture site. Conclusions: The most prevalent effects after Covid-19 vaccination found in the literature review of the articles were headache, fever, and pain at the injection site regardless of the type of vaccine and dose administered. In conclusion, the vaccine for Covid-19 vaccination was developed in record time, with prior knowledge that the stipulated times for bringing a new biological product to the market should be respected, as tests should be conducted on a larger population than could be done in the emergency that was occurring; despite these factors against it, a vaccine was launched on the market in which similar side effects were observed to those expected in any type of biological product or vaccine already being administered to the population and that meets the stipulated time standards.Resumen. -- Abstrac. -- Planteamiento del Problema. -- Justificación. -- Objetivo. -- Pregunta de Investigación. -- Marco Teórico. -- Origen. -- Definición. -- Signos y Síntomas. -- Trasmisión. -- Detección. -- Medios Diagnósticos. -- Prevención. -- Medidas de Contención. -- Métodos para Prevenir el Contagio. -- Elementos de Protección Personal de los Profesionales de la Salud. -- Métodos de barrera del resto de la población. -- Implementación de Asepsia y Antisepsia. -- Objetivo de la Vacunación. -- Vacunas. -- Vacuna de Janssen y AstraZeneca. -- Vacuna de Subunidades Novavax y la Zf2001. -- Efectos Secundarios. -- Metodología. -- Diseño. -- Población. -- Muestra. -- Identificación. -- Variables. -- Descriptores. -- Combinación con Booleanos. -- Fuentes de información. -- Criterios de Inclusión. -- Criterios de Exclusión. -- Consideraciones Éticas. -- Resultados. -- Características de los artículos. -- Conclusiones. -- Recomendaciones. -- Referencias Bibliográficas.PregradoEnfermera Profesional77 p.application/pdfspaUniversidad Cooperativa de Colombia, Facultad de Ciencias de la Salud, Enfermería, BucaramangaEnfermeríaCiencias de la SaludBucaramangaBucaramangahttp://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/openAccessAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://purl.org/coar/access_right/c_abf2Efectos adversos de la vacunación por COVID-19 en jóvenes y adultosTrabajo de grado - Pregradohttp://purl.org/coar/resource_type/c_7a1fTextinfo:eu-repo/semantics/bachelorThesishttp://purl.org/redcol/resource_type/TPinfo:eu-repo/semantics/acceptedVersionAbad-Corpa, E., Sánchez-López, D., & Moreno-Casbas, M. T. (2021). Scoping review sobre las recomendaciones para el aislamiento domiciliario en la pandemia de COVID-19. Enfermería Clínica, 31, 94–99. https://doi.org/10.1016/J.ENFCLI.2020.05.007Aboud, F. M., Hussein, R. S., & Hassan, R. M. (2023). Safety and reported adverse effects of coronavirus disease-2019 (COVID-19) vaccines in patients with rheumatic diseases. Egyptian Rheumatologist, 45(2), 133–137. https://doi.org/10.1016/j.ejr.2022.12.003Abukhalil, A. D., Shatat, S. S., Abushehadeh, R. R., Al-Shami, N., Naseef, H. A., & Rabba, A. (2023). Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community. BMC Infectious Diseases, 23(5), 1–15. https://doi.org/10.1186/s12879-022-07974-3Aguilar Ramírez, P., Yanina Enriquez Valencia, ;, Carlos, ;, Carrillo, Q., Valencia Ayala, ; Edward, De, J., Delgado, L., & Pareja Cruz, A. (2020). Pruebas diagnósticas para la COVID-19: la importancia del antes y el después. Horizonte Médico (Lima), 20(2), e1231–e1231. https://doi.org/10.24265/HORIZMED.2020.V20N2.14Al Salmi, A., Al Khamisani, M., Al Shibli, A., & Al Maqbali, S. (2022). Adverse cutaneous reactions reported post COVID-19 vaccination in Al Buraimi governorate, Sultanate of Oman. Dermatologic Therapy, 35(11), 1–7. https://doi.org/10.1111/dth.15820Aldali, H. J., Aldali, J. A., Alotaibi, B. A., Alasiri, G. A., Alromih, A. M., Elsokkary, E. M., Aldali, A. Z., & Almeziny, A. (2023). Evaluating the Adverse Events Associated with Three Doses of the COVID-19 Vaccination in Adults in the Western Region of Saudi Arabia: A Cross-Sectional Study. Vaccines, 11(2), 266–276. https://doi.org/10.3390/vaccines11020266Alghamdi, A. N., Alotaibi, M. I., Alqahtani, A. S., Al Aboud, D., & Abdel-Moneim, A. S. (2021). BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees. Frontiers in Medicine, 8(1), 1–10. https://doi.org/10.3389/fmed.2021.760047Alkhalifah, J. M., Al Seraihi, A., Al-Tawfiq, J. A., Alshehri, B. F., Alhaluli, A. H., Alsulais, N. M., Alessa, M. M., Seddiq, W., Aljeri, T., Qahtani, M. H., Barry, M., & Al-Otaiby, M. (2023). Pattern of self-reported adverse events related to COVID-19 vaccines in Saudi Arabia: A nationwide study. Frontiers in Public Health, 11(1), 1–10. https://doi.org/10.3389/fpubh.2023.1043696Almalki, O. S., Santali, E. Y., Alhothali, A. A., Ewis, A. A., Shady, A., Fathelrahman, A. I., & Abdelwahab, S. F. (2023). The role of blood groups, vaccine type and gender in predicting the severity of side effects among university students receiving COVID-19 vaccines. BMC Infectious Diseases, 23(1), 1–11. https://doi.org/10.1186/s12879-023-08363-0Alzarea, A. I., Khan, Y. H., Alatawi, A. D., Alanazi, A. S., Alzarea, S. I., Butt, M. H., Almalki, Z. S., Alahmari, A. K., & Mallhi, T. H. (2022). Surveillance of Post-Vaccination Side Effects of COVID-19 Vaccines among Saudi Population: A Real-World Estimation of Safety Profile. Vaccines, 10(6), 924–940. https://doi.org/10.3390/vaccines10060924Andrzejczak Grzadko, S., Czudy, Z., & Donderska, M. (2021). Side effects after COVID-19 vaccinations among residents of Poland. Eur Rev Med Pharmacol Sci , 25(11), 4418–4421. https://doi.org/10.26355/eurrev_202106_26153Babaee, E., Amirkafi, A., Tehrani-Banihashemi, A., SoleimanvandiAzar, N., Eshrati, B., Rampisheh, Z., Asadi-Aliabadi, M., & Nojomi, M. (2022). Adverse effects following COVID-19 vaccination in Iran. BMC Infectious Diseases, 22(1), 247–255. https://doi.org/10.1186/s12879-022-07411-5Bakasis, A. D., Mavragani, C. P., Voulgari, P. V., Gerolymatou, N., Argyropoulou, O. D., Vlachoyiannopoulos, P. G., Skopouli, F. N., Tzioufas, A. G., & Moutsopoulos, H. M. (2022). COVID-19: Clinical features and outcomes in unvaccinated 2-dose and 3-dose vaccinated against SARS-CoV-2 patients with systemic autoimmune and autoinflammatory rheumatic diseases. Journal of Autoimmunity, 131(1), 1–6. https://doi.org/10.1016/j.jaut.2022.102846Chong-Valbuena, A., De-Jesús-María, I., Agurto-Ramírez, A., Puchades-Gimeno, F., & Melero-García, M. (2022). Safety of Pfizer-BioNTech vaccine in a cohort of healthcare providers: Differences between naïve and previously infected by SARS-CoV-2. Vaccine, 40(28), 3818–3820. https://doi.org/10.1016/j.vaccine.2022.05.015Corominas, J., Garriga, C., Prenafeta, A., Moros, A., Cañete, M., Barreiro, A., González-González, L., Madrenas, L., Güell, I., Clotet, B., Izquierdo-Useros, N., Raïch-Regué, D., Gallemí, M., Blanco, J., Pradenas, E., Trinité, B., Prado, J. G., Blanch-Lombarte, O., Pérez-Caballero, R., … Ferrer, L. (2023). Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial. The Lancet Regional Health - Europe, 28(1), 1–17. https://doi.org/10.1016/j.lanepe.2023.100613Corum J., & Zimmer C. (2021). Cómo funciona la vacuna contra la COVID-19 de Pfizer-BioNTech. The New York Time. https://www.nytimes.com/es/interactive/2021/health/pfizer-biontech-vacuna-covid.htmlDhamanti, I., Suwantika, A. A., Adlia, A., Yamani, L. N., & Yakub, F. (2023). Adverse Reactions of COVID-19 Vaccines: A Scoping Review of Observational Studies. International Journal of General Medicine, 16(1), 609–618. https://doi.org/10.2147/IJGM.S400458Díaz Castrillón, F., & Toro Montoya, A. I. (2020). Artículo de revisión SARS-CoV-2/COVID-19: el virus, la enfermedad y la pandemia SARS-CoV-2/COVID-19: The virus, the disease and the pandemic. Medicina & Laboratorio, 24(3), 183–205. https://dialnet.unirioja.es/servlet/articulo?codigo=8741673Ebinger, J. E., Lan, R., Sun, N., Wu, M., Joung, S., Botwin, G. J., Botting, P., Al-Amili, D., Aronow, H., Beekley, J., Coleman, B., Contreras, S., Cozen, W., Davis, J., Debbas, P., Diaz, J., Driver, M., Fert-Bober, J., Gu, Q., … Minissian, M. B. (2021). Symptomology following mRNA vaccination against SARS-CoV-2. Preventive Medicine, 153(1), 1–8. https://doi.org/10.1016/j.ypmed.2021.106860Enayatrad, M., Mahdavi, S., Aliyari, R., Sahab-Negah, S., Nili, S., Fereidouni, M., Mangolian Shahrbabaki, P., Ansari-Moghaddam, A., Heidarzadeh, A., Shahraki-Sanavi, F., Fateh, M., Khajeha, H., Emamian, Z., Behmanesh, E., Sheibani, H., Abbaszadeh, M., Jafari, R., Valikhani, M., Binesh, E., … Emamian, M. H. (2023a). Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system. BMC Infectious Diseases, 23(1), 150. https://doi.org/10.1186/s12879-023-08103-4Enayatrad, M., Mahdavi, S., Aliyari, R., Sahab-Negah, S., Nili, S., Fereidouni, M., Mangolian Shahrbabaki, P., Ansari-Moghaddam, A., Heidarzadeh, A., Shahraki-Sanavi, F., Fateh, M., Khajeha, H., Emamian, Z., Behmanesh, E., Sheibani, H., Abbaszadeh, M., Jafari, R., Valikhani, M., Binesh, E., … Emamian, M. H. (2023b). Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system. BMC Infectious Diseases, 23(1), 150–165. https://doi.org/10.1186/s12879-023-08103-4Ferrara, P., Ponticelli, D., Losa, L., Romeo, C., Magliuolo, R., Vitale, A., Zampella, A., Alleanza, L., Borrelli, M., Schiavone, B., & Mantovani, L. G. (2023). Risk of Repeated Adverse Effects following Booster Dose of mRNA COVID-19 Vaccine: Results from the MOSAICO Study. Vaccines, 11(2), 247–261. https://doi.org/10.3390/vaccines11020247Fraiman, J., Erviti, J., Jones, M., Greenland, S., Whelan, P., Kaplan, R. M., & Doshi, P. (2022). Serious adverse events of special interest following mRNA COVID-19 vaccination in randomized trials in adults. Vaccine, 40(40), 5798–5805. https://doi.org/10.1016/j.vaccine.2022.08.036Galanis, P., Katsiroumpa, A., Vraka, I., Chrysagi, V., Siskou, O., Konstantakopoulou, O., Katsoulas, T., Gallos, P., & Kaitelidou, D. (2023). Prevalence and risk factors of adverse effects after the first COVID-19 booster dose: evidence from Greece. Vacunas, 24(3), 210–217. https://doi.org/10.1016/j.vacun.2023.05.005Gedik, M. S., Kilci, A. İ., Hakkoymaz, H., Küçük, Ö. F., Solak, Y., Basan, N. M., & Çıkrıkçı, Y. E. (2023). Evaluation of patients of vaccine side effects after the COVID-19 vaccine. Revista Da Associacao Medica Brasileira, 69(1), 147–152. https://doi.org/10.1590/1806-9282.20221035Giuliano, A., Kuter, B., Pilon‐Thomas, S., Whiting, J., Mo, Q., Leav, B., Sirak, B., Cubitt, C., Dukes, C., Isaacs‐Soriano, K., Kennedy, K., Ball, S., Dong, N., Jain, A., Hwu, P., & Lancet, J. (2023). Safety and immunogenicity of a third dose of mRNA‐1273 vaccine among cancer patients. Cancer Communications, 43(7), 749–764. https://doi.org/10.1002/cac2.12453Hammershaimb, E. A., Campbell, J. D., & O’Leary, S. T. (2023). Coronavirus Disease-2019 Vaccine Hesitancy. Pediatric Clinics of North America, 70(2), 243–257. https://doi.org/10.1016/j.pcl.2022.12.001INSPMX. (2020). ¿Qué son los coronavirus? Instituto Nacional Salud Mexico. https://insp.mx/nuevo-coronavirus-2019/que-es-nuevo-coronavirus.htmlIzak, M., Stoyanov, E., Dezuraev, K., & Shinar, E. (2022). Correlation of Anti-SARS-CoV-2 S1-specific IgG antibody levels and adverse events following vaccination with BNT162b2 mRNA COVID-19 vaccine in healthcare workers. Vaccine, 40(3), 428–431. https://doi.org/10.1016/j.vaccine.2021.11.082Jahan, N., Rahman, F. I., Saha, P., Ether, S. A., Roknuzzaman, A. S. M., Sarker, R., Kalam, K. T., Haq, K., Nyeen, J., Himi, H. Z., Nazmul Hossain, M., Chowdhury, M. H., Uddin, M. M., & Alam, N. H. (2021). Side effects following administration of the first dose of Oxford-AstraZeneca’s covishield vaccine in Bangladesh: A cross-sectional study. Infectious Disease Reports, 13(4), 888–901. https://doi.org/10.3390/IDR13040080Jorda, A., Bergmann, F., Ristl, R., Radner, H., Sieghart, D., Aletaha, D., & Zeitlinger, M. (2023). Association between reactogenicity and immunogenicity after BNT162b2 booster vaccination: a secondary analysis of a prospective cohort study. Clinical Microbiology and Infection, 29(9), 1188–1195. https://doi.org/10.1016/j.cmi.2023.05.028Kanokudom, S., Assawakosri, S., Suntronwong, N., Chansaenroj, J., Auphimai, C., Nilyanimit, P., Vichaiwattana, P., Thongmee, T., Yorsaeng, R., Duangchinda, T., Chantima, W., Pakchotanon, P., Srimuan, D., Thatsanatorn, T., Klinfueng, S., Mongkolsapaya, J., Sudhinaraset, N., Wanlapakorn, N., Honsawek, S., & Poovorawan, Y. (2022). Comparison of the reactogenicity and immunogenicity of a reduced and standard booster dose of the mRNA COVID-19 vaccine in healthy adults after two doses of inactivated vaccine. Vaccine, 40(39), 5657–5663. https://doi.org/10.1016/j.vaccine.2022.08.033Karaali, R., Öykü Dinç, H. Ö., İnanç Balkan, İ., Can, G., Keskin, E., Çolak, H., Daşdemir, F. O., Aydoğan, O., Budak, B., Kaya, S. Y., Kocazeybek, B., & Saltoğlu, N. (2023). Homologous or heterologous COVID-19 vaccine schemes: comparison of immune responses and side effects. Diagnostic Microbiology and Infectious Disease, 107(2), 1–6. https://doi.org/10.1016/j.diagmicrobio.2023.116017Kaur, S., Singh, A., Saini, S., Rohilla, L., Kaur, J., Chandi, A., Kaur, G., Singh, M., Kumar, P., Soni, S., Kajal, K., Naik, N., Malhotra, P., Verma, S., Gupta, M., Devnani, M., Das, K., Pandav, S., & Puri, G. D. (2022). Reporting adverse events of ChAdOx1 nCoV-19 coronavirus vaccine (Recombinant) among the vaccinated healthcare professionals: A cross-sectional survey. Indian Journal of Medical Research, 155(1), 123–129. https://doi.org/10.4103/ijmr.ijmr_1221_21Kermer, P., Abdalla, Y., Klein, G., & Lüers, C. (2023). Acute adverse events of Sars-CoV2 vaccines: Experiences from a health care worker vaccination campaign in two municipal hospitals in northwest Germany. Vaccine: X, 13(1), 1–6. https://doi.org/10.1016/j.jvacx.2022.100257Lee, K. M. N., Junkins, E. J., Luo, C., Fatima, U. A., Cox, M. L., & Clancy, K. B. H. (2022). Investigating trends in those who experience menstrual bleeding changes after SARS-CoV-2 vaccination. Science Advances, 8(28), 1–15. https://doi.org/10.1126/sciadv.abm7201Li, D., Debbas, P., Mujukian, A., Cheng, S., Braun, J., McGovern, D. P. B., Melmed, G. Y., Banty, A., Feldman, E., Ha, C., Lee, S., Rabizadeh, S., Stein, T., Solomon, T., Syal, G., Targan, S., Vasiliauskas, E., Ziring, D., Bonthala, N., … Damas, O. (2023). Postvaccination Symptoms After a Third Dose of mRNA SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease: Results From CORALE-IBD. Inflammatory Bowel Diseases, 29(6), 883–887. https://doi.org/10.1093/ibd/izac174Majumder, M. A. A., Singh, K., Johnson, W., Rajasundaram, A., Gupta, S., Gaur, U., Kumar, S., Chatterjee, M., Fazle Rabbi, A. M., Sangishetti, V. P., Rahman, S., Campbell, M. H., Harewood, H., Bharatha, A., Krishnamurthy, K., Kabir, R., Parsa, A. D., Mohammmad, S., Haque, M., & Razzaque, M. S. (2023). Evaluation of Short-Term Side Effects Following the First Dose of COVID-19 Vaccines Among Physicians and Dentists: A Cross-Sectional Study from India. Journal of Multidisciplinary Healthcare, 16(2), 161–174. https://doi.org/10.2147/JMDH.S390364Mallah, S. I., Alawadhi, A., Jawad, J., Wasif, P., Alsaffar, B., Alalawi, E., Mohamed, A. M., Butler, A. E., Alalawi, B., Qayed, D., Almahari, S. A., Mubarak, A., Mubarak, A., Saeed, S., Humaidan, A., Kumar, N., Atkin, S., & Alqahtani, M. (2023). Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals. Vaccine, 41(12), 1925–1933. https://doi.org/10.1016/j.vaccine.2023.01.032Marfoh, K., Samba, A., Okyere, E., Acheampong, F., Owusu, E., Darko, D. N. A., Zakariah, J., Mensa, H., Aidoo, E., & Mohammed, Y. (2023). Adverse events following immunisation (AEFI) of COVISHIELD vaccination among healthcare workers in Ghana. BMJ Open, 13(6), e061643. https://doi.org/10.1136/bmjopen-2022-061643Mascellino, M. T., Di Timoteo, F., De Angelis, M., & Oliva, A. (2021). Overview of the Main Anti-SARS-CoV-2 Vaccines: Mechanism of Action, Efficacy and Safety. Infection and Drug Resistance, 14(1), 3459–3476. https://doi.org/10.2147/IDR.S315727McMahon, D. E., Amerson, E., Rosenbach, M., Lipoff, J. B., Moustafa, D., Tyagi, A., Desai, S. R., French, L. E., Lim, H. W., Thiers, B. H., Hruza, G. J., Blumenthal, K. G., Fox, L. P., & Freeman, E. E. (2021). Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: A registry-based study of 414 cases. Journal of the American Academy of Dermatology, 85(1), 46–55. https://doi.org/10.1016/j.jaad.2021.03.092Melián-Rivas, A., Calcumil-Herrera, P., Boin-Bakit, C., Carrasco-Soto, R., Melián-Rivas, A., Calcumil-Herrera, P., Boin-Bakit, C., & Carrasco-Soto, R. (2020). Detection of COVID-19 (SARS-CoV-2) by Saliva: A Low-invasive Diagnostic Alternative. International Journal of Odontostomatology, 14(3), 316–320. https://doi.org/10.4067/S0718-381X2020000300316Menni, C., Klaser, K., May, A., Polidori, L., Capdevila, J., Louca, P., Sudre, C. H., Nguyen, L. H., Drew, D. A., Merino, J., Hu, C., Selvachandran, S., Antonelli, M., Murray, B., Canas, L. S., Molteni, E., Graham, M. S., Modat, M., Joshi, A. D., … Spector, T. D. (2021). Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. The Lancet Infectious Diseases, 21(7), 939–949. https://doi.org/10.1016/S1473-3099(21)00224-3Nassar, R. I., Barakat, M., Thiab, S., El-Hajji, F., Barqawi, H., El-Huneidi, W., Basheti, I. A., & Abu-Gharbieh, E. (2022). Web-Based Reporting of Post-Vaccination Symptoms for Inactivated COVID-19 Vaccines in Jordan: A Cross-Sectional Study. Vaccines, 11(1), 44–57. https://doi.org/10.3390/vaccines11010044Word Health Organization. (2023). Enfermedad por coronavirus (COVID-19): vacunas y seguridad de las vacunas. WHO. https://www.who.int/es/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccinesOrganización Panamericana de la Salud. (2021). La COVID-19 y Adultos Mayores -. PAHO. https://www.paho.org/es/envejecimiento-saludable/covid-19-adultos-mayoresPignatti, P., Ramirez, G. A., Russo, M., Marraccini, P., Nannipieri, S., Asperti, C., Torre, F. Della, Tiri, A., Gatti, B. M., Gurrado, A., Meriggi, A., Benanti, G., Cilona, M. B., Pigatto, P., Burastero, S. E., Dagna, L., & Yacoub, M.-R. (2023). Hypersensitivity reactions to anti-SARS-CoV-2 vaccines: Basophil reactivity to excipients. Vaccine, 41(32), 4693–4699. https://doi.org/10.1016/j.vaccine.2023.06.039Rayamajhi, S., Rafi, Md. A., Tripathi, N., Dongol, A. S., Pandey, M., Rayamajhi, S., Bhandari, S., Shrestha, P., Hasan, M. T., & Hossain, Md. G. (2022). Adverse events following immunization with ChAdOx1 nCoV-19 and BBIBP-CorV vaccine: A comparative study among healthcare professionals of Nepal. PLOS ONE, 17(8), 1–10. https://doi.org/10.1371/journal.pone.0272729Roche Farma, S. A. (2022). Patología. Roche Plus. https://www.rocheplus.es/areas-terapeuticas/covid-19/patologia.htmlRomero Saritama, J., Simaluiza, J., & Fernandez, H. (2021). Medidas de prevención para evitar el contagio por la COVID-19: de lo cotidiano a lo técnico-científico. Revista Española de Salud Publica, 95(1), 1–14. https://www.scielosp.org/article/resp/2021.v95/e202104051/es/Rosen, J. E., Chang, S. S. E., Williams, S., Lee, J. S., Han, D. H., Agrawal, N., Joo, J. H., Hsieh, G., Reinecke, K., & Liao, J. M. (2023). Association between Risk Communication Format and Perceived Risk of Adverse Events after COVID-19 Vaccination among US Adults. Healthcare (Switzerland), 11(3), 380–391. https://doi.org/10.3390/healthcare11030380Safarnezhad Tameshkel, F., Abedin Dargoush, S., Goudarzi, M., Tabibzadeh, A., Ghiaseddin, A., Ranjbar, M., Alimohamadi, Y., Zamani, F., Vaez, A., Rahimian, N., Jamshidi Makiani, M., Divsalar, F., Gholizadeh, E., & Karbalaie Niya, M. H. (2023). A Retrospective Study on the Gam-COVID-Vac (Sputnik V) COVID-19 Vaccine Short-Term Efficacy and Side Effects in Iranian Healthcare Providers. Archives of Clinical Infectious Diseases, 18(3), 1–6. https://doi.org/10.5812/archcid-133173Sen, P., Ravichandran, N., Nune, A., Lilleker, J. B., Agarwal, V., Kardes, S., Kim, M., Day, J., Milchert, M., Gheita, T., Salim, B., Velikova, T., Gracia-Ramos, A. E., Parodis, I., O’Callaghan, A. S., Nikiphorou, E., Chatterjee, T., Tan, A. L., Cavagna, L., … Zimba, O. (2023). COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study. Rheumatology (United Kingdom), 62(1), 65–76. https://doi.org/10.1093/rheumatology/keac305Sheng, W. H., Ieong, S. M., Lin, P. H., Hsieh, M. J., Yang, H. C., Pan, C. F., Chao, T. L., Chang, S. Y., & Chang, S. C. (2023). Immunogenicity and safety of third-dose mRNA COVID-19 vaccines in healthy adults previously vaccinated with two doses of the ChAdOx1 vaccine. Journal of the Formosan Medical Association, 122(2), 121–131. https://doi.org/10.1016/j.jfma.2022.09.004Siti, F., Iwan, S. D., Muflih, M., Thomas Aquino Erjinyuare, A., Rachmat, S., & Ahmat, P. (2022). Factors Associated with Adverse Events Following the First Dose of COVID-19 Immunization in Indonesia. Korean Journal of Adult Nursing, 34(3), 249–257. https://doi.org/10.7475/kjan.2022.34.3.249Tanaka, H., Mukai, J., Kushibiki, K., Mizushima, S., Maeda, K., Fujimoto, Y., Sawada, R., Oda, M., Okuda, H., Yamaki, M., Hashiguchi, S., Kawai, I., Kawaguchi, I., Masuda, N., & Matsushita, H. (2023). Effect of the third dose of BNT162b2 COVID-19 mRNA vaccine on anti-SARS-CoV-2 antibody levels in healthcare workers. Vaccine, 41(2), 365–371. https://doi.org/10.1016/j.vaccine.2022.11.049Taşlidere, B., Sönmez, E., & Özdemır, S. (2023). Evaluation of patients admitted to the emergency department after Coronavac (Sinovac) vaccination? Journal of Experimental and Clinical Medicine (Turkey), 40(1), 80–84. https://doi.org/10.52142/omujecm.40.1.17Torres, E. S., Nava Leyva, H., Teresa, A., García, R., Sánchez González, F. J., Huerta, G., & || G. (2020). Equipo de protección personal y COVID-19. Cirujano General, 42(2), 116–123. https://doi.org/10.35366/95370Word Health Organization. (n.d.). COVID-19: cronología de la actuación de la OMS. Organización Mundial de La Salud. Retrieved September 11, 2023, from https://www.who.int/es/news/item/27-04-2020-who-timeline---covid-19Word Health Organization. (2020). Coronavirus. WHO. https://www.who.int/es/health-topics/coronavirus#tab=tab_1Word Health Organization. (2021). Preguntas y respuestas sobre la transmisión de la COVID-19. Www.Who.Int. https://www.who.int/es/news-room/questions-and-answers/item/coronavirus-disease-covid-19-how-is-it-transmittedXiao, N., Xu, X., Ma, Z., Yu, X., Feng, Y., Li, B., Liu, Y., He, G., Fan, J., Li, B., & Zhao, X. (2023). Sleep quality was associated with adverse reactions after coronavirus disease 2019 vaccination among healthcare workers: A longitudinal paired study. Frontiers in Behavioral Neuroscience, 16(1), 1–10. https://doi.org/10.3389/fnbeh.2022.867650Zeitoun, A., Hallit, S., Chehade, S., Ibrahim, A., Helali, M., Allam, C., & Karam, R. (2023). A 1-year analysis of adverse events following COVID-19 vaccination in Lebanon: a retrospective study. Journal of Pharmaceutical Policy and Practice, 16(1), 24–36. https://doi.org/10.1186/s40545-023-00528-1Covid-19Efectos adversosVacunaciónCovid-19Literature reviewAdverse effectsVaccinationPublicationCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8805https://repository.ucc.edu.co/bitstreams/51cebfb5-ff87-469e-9c9c-1f37be41314f/download4460e5956bc1d1639be9ae6146a50347MD51LICENSElicense.txtlicense.txttext/plain; charset=utf-84334https://repository.ucc.edu.co/bitstreams/7778d59f-e819-47a7-a690-98379fe77b71/download3bce4f7ab09dfc588f126e1e36e98a45MD52ORIGINAL2024_Acta.pdf2024_Acta.pdfapplication/pdf140042https://repository.ucc.edu.co/bitstreams/4622c88d-a362-4070-9411-2b694c45d09c/download0a6425b3e32dd933039ed3fe876bf318MD532024_Tesis.pdf2024_Tesis.pdfapplication/pdf718587https://repository.ucc.edu.co/bitstreams/06442f88-82f8-46f4-a993-cd0733b831a3/download43e9c7e9b74b11d5ad6d9ea6cdb930c3MD542024_Licencia.pdf2024_Licencia.pdfapplication/pdf266562https://repository.ucc.edu.co/bitstreams/61ead119-71cd-4c80-9a17-7b20d1e2cd0c/downloadb06d0e01374e60127e2bb8dd6458750bMD55TEXT2024_Acta.pdf.txt2024_Acta.pdf.txtExtracted texttext/plain1149https://repository.ucc.edu.co/bitstreams/1aaca000-7d5e-43a3-9d97-c823533511cc/download56bbb4247460312c49fdbecb2ef05710MD562024_Tesis.pdf.txt2024_Tesis.pdf.txtExtracted texttext/plain101082https://repository.ucc.edu.co/bitstreams/85003123-cae1-4b49-90c0-ebcfb1149764/download776071ce79c3e8d0d21a21c5e41976b7MD582024_Licencia.pdf.txt2024_Licencia.pdf.txtExtracted texttext/plain5926https://repository.ucc.edu.co/bitstreams/51a89db6-e284-4ac7-94ad-d706a244155f/download7c3dd69c76a0e5599bd3ff2f189ae271MD510THUMBNAIL2024_Acta.pdf.jpg2024_Acta.pdf.jpgGenerated Thumbnailimage/jpeg11390https://repository.ucc.edu.co/bitstreams/b39a6e45-bc71-498e-b159-8666a3a63fa0/download17f574431e6e5aeb0eb9f58aded65ad0MD572024_Tesis.pdf.jpg2024_Tesis.pdf.jpgGenerated Thumbnailimage/jpeg7726https://repository.ucc.edu.co/bitstreams/4e66b7fc-c551-4f1e-b36c-211ed63950ab/download98e13e821c95014cd604061e84e74f5fMD592024_Licencia.pdf.jpg2024_Licencia.pdf.jpgGenerated Thumbnailimage/jpeg11922https://repository.ucc.edu.co/bitstreams/4ee33d13-ebcb-4e23-8b77-bbc057658061/downloadb712f1c96592862d07eddc9f185bd545MD51120.500.12494/56294oai:repository.ucc.edu.co:20.500.12494/562942024-07-12 03:06:59.763http://creativecommons.org/licenses/by-nc-nd/4.0/Attribution-NonCommercial-NoDerivatives 4.0 Internationalrestrictedhttps://repository.ucc.edu.coRepositorio Institucional Universidad Cooperativa de Colombiabdigital@metabiblioteca.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 |